# PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)

> **NCT03449524** · PHASE2 · TERMINATED · sponsor: **Complexa, Inc.** · enrollment: 69 (actual)

## Conditions studied

- PAH

## Interventions

- **DRUG:** 75mg CXA-10
- **DRUG:** 150mg CXA-10
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03449524
- **Lead sponsor:** Complexa, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-01
- **Primary completion:** 2020-08-05
- **Final completion:** 2020-08-05
- **Target enrollment:** 69 (ACTUAL)
- **Why stopped:** LOE
- **Last updated:** 2020-08-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03449524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03449524, "PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03449524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*